SETD2 and renal cell carcinoma: Further statistical analysis revealed non-hotspot mutations within SETD2 (Fig. 1B) with missense mutations predominating in NSCLC, melanoma, and colorectal cancer, whereas truncating mutations predominated in renal cell carcinoma (Fig. 1C).